Eli Lil­ly silent­ly walks away from a trou­bled $690M al­liance af­ter BTK drug floun­ders in PhII

Eli Lil­ly has un­cer­e­mo­ni­ous­ly swept away a mid-stage im­munol­o­gy pro­gram for their BTK in­hibitor LY3337641, shrug­ging off a $690 mil­lion pact for the im­munol­o­gy drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER